Click here to listen to today’s Diabetes Health in the News Podcast!
Researchers at Hvidovre Hospital in Denmark recently completed a study examining how adding liraglutide to insulin, affected hemoglobin A1c levels. Findings suggested that adding liraglutide to insulin, fails to improve hemoglobin A1c levels in patients with poorly controlled type 1 diabetes, of normal weight.
Researchers conducted a 12-week study with 40 patients to determine the efficacy of a 1.2 mg once-daily dose of liraglutide, versus a placebo add-on treatment to insulin. Not only did hemoglobin A1c levels fail to benefit from the liraglutide, but 90% of people receiving the liraglutide add-on, also experienced adverse effects, including gastrointestinal issues. Alternatively, only 65% of the placebo group experienced adverse effects.
These findings were published in Diabetes Care on September 22, 2015.